Other medication classes used in diabetes

Journal articles and book chapters

27-09-2017 | Dyslipidemia | Review | Article

Treatment of dyslipidemia in diabetes: Recent advances and remaining questions

Chait A, Goldberg I. Curr Diab Rep 2017; 17: 112. doi: 10.1007/s11892-017-0942-8

04-09-2017 | Nephropathy | Review | Article

GLP-1 and the kidney: From physiology to pharmacology and outcomes in diabetes

Nat Rev Nephrol 2017; 13: 605–628. doi: 10.1038/nrneph.2017.123

18-07-2017 | Gastrointestinal disorders | Review | Article

Gastroparesis: Medical and therapeutic advances

Navas CM, Patel NK, Lacy BE. Dig Dis Sci 2017; 62: 2231–2240. doi: 10.1007/s10620-017-4679-7

28-04-2017 | Retinopathy | Article

Influence of baseline diabetic retinopathy status on initial anatomical response of intravitreal ranibizumab therapy for diabetic macular oedema

Eye 2017; 31: 1358–1364. doi: 10.1038/eye.2017.69

28-04-2017 | Retinopathy | Review | Article

Oxidative stress and diabetic retinopathy: Development and treatment

Eye 2017; 31: 1122–1130. doi: 10.1038/eye.2017.64

27-04-2017 | Cardiovascular disorders | Review | Article

Blood pressure management in patients with type 2 diabetes mellitus

Hypertension 2017; 40: 721–729. doi: 10.1038/hr.2017.55

21-03-2017 | Retinopathy | Review | Article

A review of ranibizumab for the treatment of diabetic retinopathy

Stewart MW. Ophthalmol Ther 2017; 6: 33–47. doi: 10.1007/s40123-017-0083-9

25-02-2017 | Macular edema | Article

Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema

Bahrami B et al. Graefes Arch Clin Exp Ophthalmol 2017; 255: 1133–1140. doi: 10.1007/s00417-017-3624-y

16-02-2017 | Type 2 diabetes | In practice | Article

The role of the pharmacist in managing type 2 diabetes with glucagon-like peptide-1 receptor agonists as add-on therapy

Meece J. Adv Ther 2017; 34: 638–657. doi: 10.1007/s12325-017-0491-1

14-02-2017 | Macular edema | Review | Article

Therapeutic options in refractory diabetic macular edema

Shah SU, Maturi RK. Drugs 2017; 77: 481–492. doi: 10.1007/s40265-017-0704-6

02-02-2017 | Cardiovascular disorders | Review | Article

Diabetes secondary to treatment with statins

Laakso M, Kuusisto J. Curr Diab Rep 2017; 17: 10. doi: 10.1007/s11892-017-0837-8

28-01-2017 | Dyslipidemia | Review | Article

Treatment of dyslipidemias to prevent cardiovascular disease in patients with type 2 diabetes

Khavandi M et al. Curr Cardiol Rep 2017; 19: 7. doi: 10.1007/s11886-017-0818-1

30-09-2016 | SGLT2 inhibitors | Article

Combination therapy with glucagon-like peptide-1 analogues and sodium-glucose cotransporter-2 inhibitors in the management of diabesity: the real world experience

Deol H et al. Endocrine 2017; 55: 173–178. doi: 10.1007/s12020-016-1125-0

16-09-2016 | Dyslipidemia | Review | Article

PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD

Nat Rev Endocrinol 2017; 13: 36–49. doi: 10.1038/nrendo.2016.135

16-07-2015 | Retinopathy | Book chapter | Article

A basic scientific understanding of diabetic retinopathy

In: Managing Diabetic Eye Disease in Clinical Practice. Edited by Singh RP. Springer International Publishing, 2015. doi: 10.1007/978-3-319-08329-2_2